Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals has raised approximately $3.99 million before costs through the exercise of listed options and a shortfall placement to sophisticated, long-term shareholders at a discounted issue price. The funding lifts the company’s proforma cash balance to about $5.56 million, supported by an existing $3 million receivables-based debt facility, significantly strengthening its working capital as it scales its AlgoraeRx commercial portfolio and advances its AlgoraeOS R&D pipeline.
The improved balance sheet positions Algorae to capitalise on recent commercial and scientific momentum, underpinning its dual strategy of AI-driven drug-combination discovery and expansion of its medicines distribution business. For stakeholders, the raise signals enhanced financial capacity to pursue growth initiatives across both its AI platform and pharmaceutical commercialisation operations in Australia and New Zealand.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations and guide preclinical research, while its AlgoraeRx arm sources, licenses and supplies generic and specialty medicines in Australia and New Zealand.
YTD Price Performance: 28.57%
Average Trading Volume: 1,488,699
Technical Sentiment Signal: Buy
Current Market Cap: A$31.7M
Learn more about 1AI stock on TipRanks’ Stock Analysis page.